

2020

THE NATIONAL LAW JOURNAL

TRAILBLAZERS

HEALTH CARE | LIFE SCIENCE



JANE M. LOVE
GIBSON, DUNN & CRUTCHER LLP

PIONEER SPIRIT Starting with an undergraduate degree in biology and a minor in chemistry, Jane Love earned a Ph.D. in molecular biology. After a postdoctoral research position, she worked in a pharmacology laboratory with researchers who had attended law school. She became intrigued by the legal aspects of research. “So I went from the lab bench to law.”

TRAILS BLAZED Love recently represented Novartis AG’s multiple sclerosis drug Gilenya in cases impacting patent owners and challengers across the pharmaceutical and biotech industries. The passing of the America Invents Act and the Biologics Price Competition and Innovation Act in recent years has brought a continuous line of new pharmaceutical and biotech products to market. “But this law made the patent term related to these patents that all stem from a particular line of research unclear.” In *Novartis v. Ezra* and *Novartis v. Breckenridge*, she helped clarify a line of existing cases that questioned the validity of patent terms. “Across the industry, it gave patent owners and challengers clarity on what terms stay in effect under the America Invents Act.” As a dedicated advocate for diversity and inclusion, Love also mentors younger attorneys, offering places on litigation teams and other training opportunities. “Many of the people I work with have science training. That aspect enhances diversity across the teams a little more easily, which adds value to the kind of advice we provide.”

FUTURE EXPLORATIONS Love sees the rise of artificial intelligence and big data helping to answer unknown health care-related problems. “The ability to address those problems will come from places that are different from what we’ve seen in the past. We have a lot of data from decades of research which will be used in ways we can’t predict right now but will provide enormous value going forward.”